Xeris Biopharma Holdings Inc. Updates on Revenue Outlook and Stock Performance
2026 Guidance Revision
On November 6, 2026, Xeris Biopharma Holdings Inc. announced a revision of its 2026 financial guidance. The company now projects total revenue for the year to range between $395 million and $405 million. This adjustment represents an upward revision from previously disclosed figures and is intended to reflect stronger commercial traction of its liquid‑stable injectable platforms.
2030 Revenue Target
Simultaneously, Xeris reiterated its long‑term ambition, targeting more than $1 billion in total revenue by 2030. The company’s management highlighted that this goal aligns with its strategy of expanding the adoption of its novel formulation technology across the health‑care market.
Impact on Share Price
The guidance update coincided with a notable move in the company’s equity. On November 5, 2026, Xeris shares reached a new 52‑week high of $13.74, surpassing the previous peak of $13.58 set on September 29, 2026. This price advance is directly linked to investor optimism surrounding the enhanced revenue outlook and the firm’s ongoing product development pipeline.
Q3 2026 Earnings Preview
An earnings preview released on November 4, 2026, provided additional context for the upcoming quarterly results. While the preview did not disclose specific earnings figures, it indicated that Xeris is preparing to report its third‑quarter 2026 financial performance, which will be critical for assessing the effectiveness of its revenue growth strategy.
Company Profile
Xeris Biopharma Holdings Inc. is a Nasdaq‑listed health‑care company with a market capitalization of approximately $1.91 billion. The firm specializes in offering formulation technology platforms that enable the development and commercialization of ready‑to‑use, liquid‑stable injectables. Its operational model focuses on delivering these innovative solutions to customers worldwide through its subsidiary network.
Financial Highlights (as of 2026‑11‑04)
- Close Price: $13.08
- 52‑Week Range: $5.25 – $13.74
- Price‑to‑Earnings Ratio: –93.05 (negative, reflecting current losses)
The latest guidance and revenue target updates are expected to influence the company’s valuation and investor sentiment moving forward.
